Hospitals

Turner Imaging Systems and Siemens Healthineers Announce New Business Relationship Agreement

Tuesday, July 7, 2020 - 1:02pm

Turner Imaging Systems has entered into a Master Resellers agreement which will add the Smart-C Mini C-Arm to the Siemens Healthineers portfolio of radiology and imaging products.

Key Points: 
  • Turner Imaging Systems has entered into a Master Resellers agreement which will add the Smart-C Mini C-Arm to the Siemens Healthineers portfolio of radiology and imaging products.
  • The Smart-C Mini C-Arm, developed by Turner Imaging Systems, is a fully functional mini-C-arm system that is battery operated and hand-transportable, improving the way fluoroscopy is performed.
  • Turner Imaging Systems, based in Orem, Utah, recently received FDA 510(k) clearance of the Smart-C Mini C-Arm portable fluoroscopy X-ray imaging device.
  • As a developer of advanced X-ray imaging systems, the inclusion of the Smart-C Mini C-Arm in the Siemens portfolio represents a significant milestone, not only for Turner Imaging Systems but also for the imaging communitypatients and clinicians.

Hemovent Extends Series B Financing Round Raising Additional $5.5+ Million

Tuesday, July 7, 2020 - 2:30pm

Hemovent GmbH announced today that it has closed an extension of its Series B financing round, raising an additional $5.5+ million from existing investors led by MIG Funds .

Key Points: 
  • Hemovent GmbH announced today that it has closed an extension of its Series B financing round, raising an additional $5.5+ million from existing investors led by MIG Funds .
  • Hemovent previously announced that it had closed a $5.2 million Series B round on the expectation of a regulatory approval of its MOBYBOXECMO/ECLS system.
  • Extension of the Series B round is testament to investors confidence in the Hemovent team and the considerable market opportunity ahead of them, said Matthias Guth of MIG Funds.
  • Hemovent is an emerging medical device company with a proprietary platform technology for heart and lung support.

LivaNova Announces Publication Detailing the Design of the RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression

Tuesday, July 7, 2020 - 2:00pm

Working with CMS, we designed RECOVER the largest clinical study of its kind to further evaluate and confirm the efficacy of VNS Therapy for TRD, said Bryan Olin, LivaNova Senior Vice President for Clinical, Quality and Regulatory Affairs.

Key Points: 
  • Working with CMS, we designed RECOVER the largest clinical study of its kind to further evaluate and confirm the efficacy of VNS Therapy for TRD, said Bryan Olin, LivaNova Senior Vice President for Clinical, Quality and Regulatory Affairs.
  • More information about the RECOVER study is available at ClinicalTrials.gov and at recovervns .com.
  • LivaNova operates as two businesses: Cardiovascular and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.), respectively.
  • These statements include, but are not limited to, statements regarding VNS Therapy and our approach to treatment-resistant depression using VNS Therapy.

CytoAgents Receives Funding to Accelerate COVID-19 Clinical Trials for Cytokine Storm Treatment From Richard King Mellon Foundation

Tuesday, July 7, 2020 - 1:58pm

One of our goals is to seed quick solutions to the communitys most immediate healthcare needs, said Sam Reiman, Director of the Richard King Mellon Foundation.

Key Points: 
  • One of our goals is to seed quick solutions to the communitys most immediate healthcare needs, said Sam Reiman, Director of the Richard King Mellon Foundation.
  • Its an honor to be selected for this funding from the Richard King Mellon Foundation, said Teresa Whalen, RPh , CEO, CytoAgents.
  • The $250,000 investment will accelerate the development of GP1681, which will be going into Phase 1 and Phase 2 human clinical trials in 2020.
  • Founded in 1947, the Richard King Mellon Foundation is the largest foundation in southwestern Pennsylvania.

Ardent Health Services Selects American Red Cross Resuscitation Suite™ Program in Enterprise-wide Agreement with HealthStream

Tuesday, July 7, 2020 - 2:25pm

HealthStream (Nasdaq: HSTM) announced today that Ardent Health Services has entered into an agreement with HealthStream to utilize the American Red Cross Resuscitation Suite program, enterprise-wide, for resuscitation skills training and certification, which will be provided through HealthStreams workforce platform.

Key Points: 
  • HealthStream (Nasdaq: HSTM) announced today that Ardent Health Services has entered into an agreement with HealthStream to utilize the American Red Cross Resuscitation Suite program, enterprise-wide, for resuscitation skills training and certification, which will be provided through HealthStreams workforce platform.
  • The Red Cross Resuscitation Suite program chosen by Ardent brings an updated, highly adaptive, competency-based solution to their healthcare teams, offering a new standard of resuscitation competency.
  • Ensuring competency of resuscitation knowledge and skills becomes more efficient, is achieved with higher quality learning effectiveness, and can be economically advantageous for health systems like Ardent with the adoption of the Red Cross Suite.
  • To learn more about the Red Cross Resuscitation Suite program and the quality improvements that hospitals and healthcare organizations are realizing from it, go to https://www.healthstream.com/solution/resuscitation/bls-als-pals .

Glytec and ThunderCat Technology Partner to Improve Glycemic Management at VA Hospitals

Tuesday, July 7, 2020 - 1:30pm

Glytec , the only provider of insulin management software across the continuum of care, and ThunderCat Technology , a Service-Disabled Veteran-Owned Small Business (SDVOSB) that delivers technology products and services to government organizations, today announced a partnership to help improve glycemic management within hospitals operated by the United States Department of Veterans Affairs (VA).

Key Points: 
  • Glytec , the only provider of insulin management software across the continuum of care, and ThunderCat Technology , a Service-Disabled Veteran-Owned Small Business (SDVOSB) that delivers technology products and services to government organizations, today announced a partnership to help improve glycemic management within hospitals operated by the United States Department of Veterans Affairs (VA).
  • Together, Glytec and ThunderCat will extend Glytecs reach into the VA health system by making Glytecs Glucommander software widely available to improve patient outcomes and reduce cost of care for the large population of veterans with diabetes.
  • However, that need is higher in VA hospitals because 25% of veteran patients are living with diabetes , compared to about 10% of the general public.
  • While inpatient glycemic management remains a broader issue across the U.S. health system, helping to improve care and outcomes at the VA is especially important and can have a very dramatic impact.

DeliverCareRx Announces Grand Opening of New Hospice Pharmacy in Southern New Jersey

Tuesday, July 7, 2020 - 1:05pm

DeliverCareRx, a market leader in home delivery pharmacy services to both chronically and terminally ill hospice patients, has announced the grand opening of its Southern New Jersey facility located in West Deptford.

Key Points: 
  • DeliverCareRx, a market leader in home delivery pharmacy services to both chronically and terminally ill hospice patients, has announced the grand opening of its Southern New Jersey facility located in West Deptford.
  • The new facility will provide hospice pharmacy services and home delivery to all of its New Jersey hospice customers, as well as those hospice customers in the Greater Philadelphia area and Northeastern US.
  • DeliverCareRx is exclusively partnered with the industrys largest hospice pharmacy services provider, based out of Montgomery, AL.
  • DeliverCareRx is very excited to open our new state of the art New Jersey pharmacy solely specialized on serving hospices and hospice patients, said Dave Krishna RPh, President and CEO of DeliverCareRx.

Dascena Receives FDA Breakthrough Device Designation for Machine Learning Algorithm for Earlier Prediction of Acute Kidney Injury

Tuesday, July 7, 2020 - 1:00pm

This is the first Breakthrough Device Designation of a cloud-based machine learning algorithm developed for the early detection of AKI.

Key Points: 
  • This is the first Breakthrough Device Designation of a cloud-based machine learning algorithm developed for the early detection of AKI.
  • Acute kidney injury commonly affects hospitalized individuals, and if not caught early, can result in dangerous outcomes for patients, said Ritankar Das, chief executive officer of Dascena.
  • Our machine learning algorithm is able to analyze patient vital sign data and determine whether a patient is at risk of developing acute kidney injury.
  • Dascena is developing machine learning diagnostic algorithms to enable early disease intervention and improve care outcomes for patients.

 Acessa Health Announces Positive Payer Coverage, with Over Half of Insured Americans Covered for the Procedure

Tuesday, July 7, 2020 - 1:00pm

(1) More than 156 million Americans are covered for the Acessa procedure, with expanded coverage over the last 12 months in Maryland, Massachusetts, North Carolina, North Dakota, Ohio, Pennsylvania, and Washington DC.

Key Points: 
  • (1) More than 156 million Americans are covered for the Acessa procedure, with expanded coverage over the last 12 months in Maryland, Massachusetts, North Carolina, North Dakota, Ohio, Pennsylvania, and Washington DC.
  • The Acessa procedure is designed to treat women with uterine fibroids and is clinically proven with long-term data as a safe alternative to hysterectomy and myomectomy.
  • (2)
    Acessa Health is a womens health innovator dedicated to advancing minimally invasive, uterine-sparing solutions for women with symptomatic fibroids.
  • Although many patients may benefit from the Acessa Procedure, this treatment is not for everyone and results may vary.

AtriCure to Announce Second Quarter 2020 Financial Results

Tuesday, July 7, 2020 - 1:00pm

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020.

Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020.
  • AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, July 28, 2020 to discuss its second quarter 2020 financial results.
  • A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCures corporate website at ir.atricure.com .
  • Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications.